GLP-1 receptor agonists aid broader outcomes in kidney disease, major analysis finds
The analysis reveals multiple benefit in patients with type 2 diabetes and obesity with cardiovascular disease, or chronic kidney disease (CKD).
List view / Grid view
The analysis reveals multiple benefit in patients with type 2 diabetes and obesity with cardiovascular disease, or chronic kidney disease (CKD).
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
Lilly has announced new findings from separate studies of Trulicity (dulaglutide) and Tradjenta (linagliptin) at the American Diabetes Association 76th Scientific Sessions.
New data from a completed Phase 3 trial show Lilly’s Trulicity (dulaglutide) 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering haemoglobin A1c (A1C) from baseline after 24 weeks of treatment.
The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies. Eli Lilly and Company's (LLY) Trulicity™ (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed with patients in mind. It comes in a single-dose pen…